Filing Details
- Accession Number:
- 0001819790-21-000043
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-11-03 19:00:18
- Reporting Period:
- 2021-11-01
- Accepted Time:
- 2021-11-03 19:00:18
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1819790 | Tarsus Pharmaceuticals Inc. | TARS | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1791249 | Michael Ackermann | C/O Tarsus Pharmaceuticals, Inc. 15440 Laguna Canyon Road, Suite 160 Irvine CA 92618 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2021-11-01 | 4,964 | $27.76 | 1,210,718 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-11-01 | 869 | $28.18 | 1,209,849 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices with the range of $27.10 to $28.07. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $28.11 to $28.27. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.